成人国产一区二区三区婷婷_日本精品一区二区三区在线视频辷_精品免费国产精品蜜桃一区二区_国产AV女高中生第一次破_W亚洲精品综合第一国产综合_国产啪视1000部免费视频

2016年10月12日，山東省眼科研究所所長、山東省眼科醫(yī)院院長、中華醫(yī)學會眼科學分會角膜病學組組長史偉云教授，受美國哈佛大學附屬麻省總院華人學者聯(lián)合會的邀請，在著名的麻省總醫(yī)院（MGH）Bulfinch樓的Ether?Dome（“乙醚廳”）就生物工程角膜研發(fā)和臨床應用情況進行了演講。Ether?Dome座無虛席，來自世界各地的專家學者認真聽取了史偉云教授的報告，并積極就史偉云教授的報告進行了提問，史偉云教授對專家的提問進行了細致的回答。
? 史偉云教授精彩的演講將各國專家的視角引向了蓬勃發(fā)展的中國眼科事業(yè)，此次演講代表著我國科學家眼科自主知識產(chǎn)權(quán)的研究應用得到世界頂尖學府的認可。

史偉云教授在著名的麻省總醫(yī)院（MGH）Bulfinch樓的Ether?Dome 進行演講

來自世界各地的眼科專家學者認真聽取史偉云教授的演講

我國約有400萬角膜盲患者，但由于我國角膜供體缺乏每年實施角膜移植復明的患者不足1萬人，很多角膜盲患者在黑暗中等待光明。山東省眼科醫(yī)院院長史偉云教授、謝立信院士團隊牽頭與中國再生醫(yī)學國際有限公司合作研發(fā)的全球首個生物工程角膜于2015年4月底獲得國家食品藥品監(jiān)督管理總局頒發(fā)的醫(yī)療器械注冊證書，2015年5月23日正式投產(chǎn)上市。作為全球首個生物工程角膜將極大地緩解我國捐獻角膜奇缺的臨床困境，為我國400萬角膜盲患者帶來復明的希望。2015年9月首例生物工程角膜臨床移植在山東省眼科研究所由謝立信院士與史偉云教授聯(lián)合主刀并獲得成功。??
? 生物工程角膜是由異種角膜經(jīng)脫細胞特殊工藝的多級處理，去除了角膜中的細胞、雜蛋白、多糖等抗原，保留了天然角膜基質(zhì)膠原蛋白結(jié)構(gòu)及透明性，生物相容性好，生物安全性高，能與周圍組織快速整合，移植角膜透明，患者視力快速恢復。這是擁有完整自主知識產(chǎn)權(quán)的高科技劃時代產(chǎn)品，在國際醫(yī)學界也引起了巨大的反響。同時該項目也作為史偉云教授與謝立信院士團隊部分重要支撐材料獲得2015年度國家科技進步二等獎。
? 為了使全球首個生物工程角膜在臨床應用中獲得更好的臨床效果，中國再生醫(yī)學國際有限公司在山東省眼科醫(yī)院建設了國內(nèi)首個培訓基地。目前全國生物工程角膜移植培訓班已經(jīng)完成了十余期培訓，累計培訓國內(nèi)外角膜移植手術醫(yī)生246人。

首屆全國生物工程角膜移植培訓班合影

全球首個生物工程角膜在臨床的成功應用在世界范圍內(nèi)同樣引起了廣泛關注，在受邀前往哈佛大學分享經(jīng)驗前，美國著名的哥倫比亞電視臺派出記者從美國專程來到山東省眼科醫(yī)院就首個生物工程角膜細節(jié)情況對史偉云教授進行了專訪。

美國最大的哥倫比亞廣播公司（CBS）電視網(wǎng)記者Adrianadiaz專程來山東省眼科醫(yī)院對史偉云教授進行專訪

史偉云教授是我國眼科角膜病專業(yè)領軍者，中華醫(yī)學會角膜病學組組長，從事眼科醫(yī)療、科研和教學工作30年，是全世界極少完成角膜手術超萬例的專家。他不僅在臨床上造福了無數(shù)的角膜病患者，還大刀闊斧進行學術創(chuàng)新，持續(xù)圍繞我國角膜供體匱乏和診治技術落后兩大難題，創(chuàng)新開展了一系列適合我國患者的診療技術和臨床轉(zhuǎn)化研究，并在全國推廣應用。

Ether?Dome內(nèi)景

近代世界第一例麻醉下的手術在Ether?Dome完成并公開演示

麻省總醫(yī)院簡介：
麻省總醫(yī)院（MGH）建立于1811年，是美國歷史最悠久的三所醫(yī)院之一，也是新英格蘭地區(qū)建立最早、規(guī)模最大的醫(yī)院和哈佛醫(yī)學院建立最早、規(guī)模最大的教學醫(yī)院。麻省總醫(yī)院出過11位諾貝爾獎得主，麻省總院是美國最大的研究型醫(yī)院，每年投入研究的經(jīng)費高達7.86億美元。
Ether?Dome簡介：
因為近代世界第一例麻醉下的手術在此完成并公開演示，讓Ether?Dome聞名于世。當時William?Morton醫(yī)生給予以患者乙醚吸入麻醉，外科醫(yī)生John?Collins?Warren（麻省總醫(yī)院、哈佛醫(yī)學院及New?England?Medical?Journal創(chuàng)始人之一）完成手術。術后Warren詢問患者感覺如何，在得到患者一再重復沒有什么疼痛的感覺確認后，Warren醫(yī)生轉(zhuǎn)身，說出了那句被寫進醫(yī)學歷史的著名的話：先生們，這不是謊話（"Gentlemen,?this?is?no?Humbug".）在Ether?Dome還陳列了當時做手術的器具、乙醚瓶，還陳列了來自古埃及底比斯的木乃伊。

Prof. Weiyun SHI was invited to share the experience in clinical application of the bioengineered cornea initiated in China with the world in the Massachusetts General Hospital

On October 12, 2016, Prof. Weiyun SHI, the director of Shandong Eye Institute, president of Shandong Eye Hospital and leader of the Corneal Disease Group of Ophthalmological Society of Chinese Medical Association, was invited by the Massachusetts General Hospital Chinese Scientists and Staff Association (MGHCSSA) to give a speech on the development and clinical application of the bioengineered cornea in the Ether Dome of Bulfinch building at Massachusetts General Hospital (MGH). Experts and scholars all over the world have come and listened to the speech carefully. Questions raised by the audience have been answered by Prof. SHI in detail.

The wonderful speech delivered by Prof. SHI has led the attention of experts from all over the world to the flourishing Chinese ophthalmology. Prof. SHI delivering a speech in MGH shows that the application of the research achievements with proprietary intellectual property rights by Chinese ophthalmologists has been recognized by one of the world-top universities.

There are about 4 million corneal blindness cases in China. However, due to the shortage of corneal donors, fewer than 10,000 patients have the opportunity to undergo corneal transplantation each year. Most of the corneal blindness patients are waiting to see the light again in dark. The first bio-engineered cornea in the world, developed cooperatively by the team led by Prof. SHI (President of Shandong Eye Hospital) and Academician Lixin XIE and China Regenerative Medicine International Limited, has obtained the Registration Certificate for Medical Device from CFDA at the end of April, 2015 and was officially put into production and market on May, 23, 2015. As the world's first bio-engineered cornea, it can greatly alleviate the clinical situation of low cornea donation rate in China, and bring the hope of regaining sight for 4 million corneal blind patients in China. The world's first bioengineered corneal clinical transplantation conducted at Shandong Eye Institute (Qingdao Eye Institute, Shandong Eye Hospital) in September 2015 was successful.

The bioengineered corneas are made from xenogeneic corneas through multilevel processing using decellularized special techniques, which remove antigens in corneas like cells, impure protein and polysaccharide and preserve the structure of natural corneal stromal collagens and their transparency. The biocompatibility is good and the biosecurity is high. They can integrate into the surrounding tissue quickly. With transparent transplanted cornea, the visual acuity of patients can be improved quickly. This is an epoch-making high-tech production with completely independent intellectual property rights. As an important part of the achievements of the team, this project has also contributed to the winning of the Second Prize of 2015 National Science and Technology Progress Award.

To gain better clinical results in the clinical application of the world’s first bioengineered cornea, China Regenerative Medicine International Limited established the first doctor training base for bio-engineered corneal transplantation at Shandong Eye Hospital. Up to now, 246 domestic and international ophthalmologists have been trained here.

The successful application of the world's first bioengineered cornea has caught the world’s attention. Before the departure for America, Prof. SHI accepted an exclusive interview with Columbia Broadcasting System on details of the first bioengineered cornea at Shandong Eye Hospital.?

Prof. SHI, a member of the Standing Committee of Chinese Medical Association and the leader of the Corneal Disease Group of Ophthalmological Society, is one of the leaders in keratopathy in China. He has been engaged in ophthalmology clinical work, scientific research and teaching for 30 years, and is one of the few experts that have completed more than 10 thousand corneal surgeries in the world. He has not only brought benefits to countless patients clinically, but also made great innovations academically. Focusing on the two major problems—shortage of donor corneas and poor diagnosis and treatment techniques, Prof. SHI has conducted innovative research to find therapeutic methods that are more suitable for Chinese patients. Some of his research achievements have been applied throughout the country.

Brief Introduction to MGH:

Founded in 1811, MGH is the third-oldest general hospital in the United States, and also the original and largest teaching hospital of Harvard Medical School and biomedical research facility located in the West End neighborhood of Boston, Massachusetts. It is also a major research hub, with an annual research budget of more than $786 million.?

Brief Introduction to Ether Dome:

The Ether Dome is a surgical operating amphitheater in the Bulfinch Building at Massachusetts General Hospital in Boston. It served as the hospital’s operating room from its opening in 1821 until 1867. It was the site of the first public demonstration of the use of inhaled ether as a surgical anesthetic on October 16, 1846. The Ether Dome event occurred when William Thomas Green Morton, a local dentist, used ether to anesthetize Edward Gilbert Abbott. John Collins Warren, the first dean of Harvard Medical School, then painlessly removed part of a tumor from Abbott's neck. After Warren had finished, and Abbott regained consciousness, Warren asked the patient how he felt. Reportedly, Abbott said, "Feels as if my neck's been scratched". Warren then turned to his medical audience and uttered: "Gentlemen, this is no Humbug". The surgical instruments, the ether inhaler, and an Egyptian mummy are displayed in the Ether Dome.

?

?

?